The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The BOD obviously have found a way to get CURRENT spending down and have predicted that they have enough to last until the end of Q1 so I will take them at their word and not your estimate based on previous cash burn.
Why the fluck would you want to that Del ? Would you rather them start to mine now and run out of money by the end of the month ? Sorry but you're starting to sound more like Toffers by the day. Chill and let this play out. Changing the BOD at this late stage would be of benefit to nobody.
EIE01 - "What is EXTREMELY frustrating is the fact the company is still in active discussions to sell the concentrate, why is it taking so long." - I believe this is linked to the ongoing tax issue that is due to be heard and possibly concluded on December 13th.
1. MT DFS details published. - I think CS stated in the AGM that it couldn't be release until given clearance by the Russia authorities.
3. Who received the VAT credits & how much more we are due (in local currency) - will probably be in the annal report and I don't think and RNS is needed for this
8. What the Logik & QVL/Mispare court cases cost EUA - will be in the annual report (2024) I would imagine
9. Update on the WUP with Gowling WLG (UK) LLP. - both due to be heard on the 13th
Del - I get that you're peeved with CS but you were the same way pre AGM and after it you were a little more upbeat. He stated in the AGM that his hands are tied as to what he can update shareholders about due to NDA's. Nobody on these boards know what the NDA's cover but I'm guessing that if the information could be released it would be. Be careful what you wish for and having someone new in post will not change the fact that the NDA's would still be in place so we'd be none the wiser.
Just going back to my original question, a pharma company is driven by profit. So if less drug is used and no drugs for side effects are needed anymore, what advantage does the pharma company get with Pre | cision? - I'll keep it simple for you Oily. 1 company has pre/cision Dox (the new standard of care). 20 other companies have standard Dox. The standard Dox becomes nigh on obsolete overnight and all their Dox business goes to the 1 company. How much profit do you think that 1 company then stands to make ?
Oil - - !Does the Pre | cision Platform bring more profit to pharma compared to the standalone drug - NO as you will likely need less drug and fewer doses"??
If Pre/cision is as good as we think and it becomes the standard of care overnight, the standalone drugs will become irrelevant. It can applied to many chemotherapies so big pharma will need it or they will see a huge fall in their profits.
Sounds promising :
https://youtube.com/live/g6ePGvdmlmw?si=GETGyT_gK18q24sv
HT - Brain lymphoma, also known as primary cerebral lymphoma or primary central nervous system lymphoma, is a rare, highly aggressive non-Hodgkin lymphoma cancer originating in the lymph tissue (white blood cells) of the brain or spinal cord, and can also be found in the eyes.